From This Year's American Thoracic Society Meeting in DC
Dr. Andy Tager (shown right) received the
Recognition Award for Scientific Accomplishments at the annual American
Thoracic Society meeting in Washington, DC, on May 21.
The Recognition Awards for
Scientific Accomplishments is given to individuals
for outstanding scientific contributions in basic or clinical research to the understanding, prevention and treatment of lung disease. Those considered for the award are recognized for either scientific contributions throughout their careers or for major contributions at a particular point in their careers.
has contributed to our understanding of pathogenic mechanisms in
fibrosis across different organs in scleroderma and related diseases. He
gave an outstanding presentation summarizing his
research work that has led to the development of potential therapies
currently being tested in clinical trials.
Scleroderma Questions Answered from Cleveland Clinic Experts
Scleroderma experts from Cleveland Clinic discussed some common questions from patients. Dr. Kristin Highland, a pulmonologist who specializes in scleroderma-associated lung disease, and rheumatologist Dr. Soumya Chatterjee answered questions about fatigue, breathing problems and gut issues related to scleroderma.
Interested in learning more about the clinical trial process? The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) offers helpful information to introduce you to clinical trials.
Find out more about common terms in the glossary, learn if clinical trials are right for you, and search for open trials currently accepting patients.
The European League Against Rheumatism (EULAR) has added two new
therapeutic statements addressing organ complications in scleroderma, updated from the 2009 recommendations. These include Raynaud Phenomenon, digital ulcers,
pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma
renal crisis, and gastrointestinal (GI) involvement. The new document increases the number of pharmacological management recommendations to 16.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.